Latest Conference Articles

In an interview with Targeted Oncology, Richard M. Stone, MD, discussed challenging subtypes of acute myeloid leukemia and therapies available to treat them.

Rajneesh Nath provides an expert's take on the evolution of risk stratification, molecular testing, and treatment of acute myeloid leukemia.

The phase 2b AIPAC study, Eftilagimod alpha was found to improve overall survival in metastatic breast cancer along with a tolerable safety profile.

Data presented at an ASCO Plenary session found that digitally monitoring patient-reported outcomes helped to improve outcomes and quality of life.

Subasumstat was found to have a manageable safety profile along with preliminary anti-tumor activity in patients with advanced or metastatic solid tumors or relapsed/refractory lymphoma.

Joseph A. Sparano, MD, who recently gave a talk during the 19th Annual School of Breast Oncology, discusses prolonging responses to therapy in patients with advanced breast cancer.

In the Chinese population of the global INVICTUS trial, ripretinib was found to have a manageable safety profile and produced a good response rate.

Compared with systemic therapy administered after cytoreductive nephrectomy, active surveillance was an option for some patients with metastatic renal cell carcinoma.

Compared with sunitinib, the combination of nivolumab an ipilimumab produced better long-term responses, with overall survival approaching 5 years.

New findings suggest that understanding subtypes of non-clear cell renal cell carcinoma is important for personalizing treatment.

James Brugarolas, MD, PhD, discusses updated survival data in patients with metastatic renal cell carcinoma.

The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.

While immunotherapy has high and durable response rates, most patients die of the disease.

During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.

Naomi B. Haas, MD, medical oncologist, discusses the potential benefits of lenvatinib for the treatment of renal cell carcinoma.

Limited data exists on the effects of palliative care in patients with kidney cancer, and more research is needed.

Shaji Kumar, MD, a hematologist at the Mayo Clinic and chair of the Plasma Cell Disorders Scientific Committee at the American Society of Hematology, discuses the standard of care in newly diagnosed myeloma.

In an interview with Targeted Oncology, Gabriela Hobbs, MD discussed the current treatment landscape for MPNs and the research that is aiming to address post-MPN acute leukemia and unmet needs for the patient population.

Eileen M. O’Reilly, MD, discusses the current treatment landscape for neuroendocrine tumors.

Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.

The future of minimal residual disease testing in chronic lymphocytic leukemia may be applicable for patients being treated with venetoclax in combination with Bruton’s tyrosine kinase inhibitors.

During the NCCN 2021 Congress: Hematologic Malignancies Natalie S. Callander, MD, discusses treatment options in relapsed/refractory multiple myeloma.

In an interview with Targeted Oncology, Alice S. Mims, MD, discussed targeting biomarkers in acute myeloid leukemia, and upfront disease management.

During the NCCN 2021 Congress: Hematologic Malignancies, Aaron T. Gerds, MD, MS, explained the risk stratification tools used in patients with myeloproliferative neoplasms.

Alice S. Mims, MD a hematologist at The Ohio State University Comprehensive Cancer Center, discusses testing and actionable mutations in newly diagnosed acute myeloid leukemia.

The 140 mg dosage was associated with a higher rate of adverse events and dose reductions.

Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.

In patients with HER2-positive, metastatic colorectal cancer, fam-trastuzumab deruxtecan-nxki led to improved responses in patients with higher HER2 expression at baseline, whereas responses were seen irrespective of RAS- and PIK3CA mutation status and blood tumor mutational burden levels.

In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.

In patients with estrogen receptor–positive, HER2-negative early breast cancer, giredestrant resulted in a greater relative reduction in Ki67 score from baseline to week 2 of a window of opportunity phase vs anastrozole.